Effectiveness of conversional metabolic and bariatric surgery on dyslipidemia and the cost of lipid-lowering medications over 4 years: a French nationwide study
Surgery for Obesity and Related Diseases · 2024
DOI: 10.1016/j.soard.2024.08.019 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Surgery for Obesity and Related Diseases, 2024. Verfasst von Jérémie Thereaux und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Digestive and Metabolic Surgery, La Cavale Blanche University Hospital, Boulevard Tanguy Prigent, Brest, France; Univ Brest, C…. Hauptthemen laut MEDLINE: Dyslipidemias, Hypolipidemic Agents, Bariatric Surgery. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The need for conversional metabolic and bariatric surgery (CMBS) is still growing. No large-scale prospective cohort studies have assessed changes in lipid-lowering treatment (LLT) after CMBS. OBJECTIVES: This study assesses and compares the effectiveness of the 4 main CMBS sequences after sleeve gastrectomy (SG) and adjustable gastric banding (AGB) on reimbursement and cost of LLT. SETTING: France. METHODS: This nationwide observational population-based cohort study analyzed data from the French National Health Insurance database. It included all patients who had undergone primary SG and AGB in France between January 1, 2012, and December 31, 2014, and followed until December 31, 2020. The study assessed LLT reimbursement evolution and costs across 4 different CMBS sequences. RESULTS: During follow-up, 6396 patients underwent the 4 CMBS sequences: SG-RYGB (Roux-en-Y gastric bypass) (n = 2400), AGB-SG (n = 2277), AGB-RYGB (n = 1173), and SG-SG (n = 546), with a rate of LLT reimbursement of 9.8%, 3.6%, 6.6%, and 7.9%, respectively, in the year before CMBS. The rates of discontinuation of treatment at 2 and 4 years were 41.9%, 35.4%, 45.6%, 20.5% and 45.6%, 31.3%, 64.3%, 31.6%, respectively. At 4 years, the median [interquartile range] annual costs (euros) per patient were significantly lower (P < .01) than the costs in the year before CMBS for each sequence: 86.8 [57.3; 136.1] versus 38.0 [.0; 64.6], 79.1 [50.5; 120.1] versus 50.4 [15.6; 64.1], 89.0 [66.5; 139.6] versus .0 [.0; 58.8], and 89.8 [66.1; 121.4] versus 63.1 [.0; 93.4]. CONCLUSIONS: Our study underlines the effectiveness of CMBS in significantly reducing the need and associated costs of LLT for patients with dyslipidemia over a 4-year period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General, Digestive and Metabolic Surgery, La Cavale Blanche University Hospital, Boulevard Tanguy Prigent, Brest, France; Univ Brest, CHU Brest, UMR 1304, Western Brittany Thrombosis Group, Brest, France.…
- Qualees, Paris, France.
- Board of the Federation Nationale des Associations Medicales de Nutrition (FNAMN), Cenon, France.
- Department of Nutrition, Pitié-Salpêtrière Hospital, Assistance Publique- Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France.
Zitieren
APA
Thereaux, J., Bennani, M., Khemis, J., Ohayon, E., Buissez, I. V., Lafourcade, A., Quiriconi, L., Philippe, C., & Oppert, J. M. (2024). Effectiveness of conversional metabolic and bariatric surgery on dyslipidemia and the cost of lipid-lowering medications over 4 years: a French nationwide study. Surgery for Obesity and Related Diseases. https://doi.org/10.1016/j.soard.2024.08.019
Vancouver
Thereaux J, Bennani M, Khemis J, Ohayon E, Buissez IV, Lafourcade A, et al. Effectiveness of conversional metabolic and bariatric surgery on dyslipidemia and the cost of lipid-lowering medications over 4 years: a French nationwide study. Surgery for Obesity and Related Diseases. 2024. doi:10.1016/j.soard.2024.08.019
BibTeX
@article{Thereaux2024,
author = {Thereaux, Jérémie and Bennani, Mohammed and Khemis, Jean and Ohayon, Elisabeth and Buissez, Isabelle Visnovec and Lafourcade, Alexandre and Quiriconi, Laëtitia and Philippe, Caroline and Oppert, Jean-Michel},
title = {Effectiveness of conversional metabolic and bariatric surgery on dyslipidemia and the cost of lipid-lowering medications over 4 years: a French nationwide study},
journal = {Surgery for Obesity and Related Diseases},
year = {2024},
doi = {10.1016/j.soard.2024.08.019}
}
EUVIMED